NYSE:PFEPharmaceuticals
Pfizer (PFE) Stock Looks Fully Priced Despite Pipeline Optimism
Pfizer stock has delivered a solid 24.3% gain over the past year, yet current valuation checks flag it as overvalued on market multiples and only middling on overall value.
Over the last 12 months, Pfizer shares are up 24.3%, which puts recent optimism in sharp focus as investors weigh how much good news is already in the price.
On the positive side, ongoing work in vaccines, oncology and partnerships such as the recent antibody drug conjugate agreement can support expectations for future...